Precision Medicine Initiative

Why Precision Medicine?

Despite clinical guidelines, biomarker testing is unevenly applied, leaving patients without access to targeted therapies.

Precision Medicine uses a patient's genetics to create personalized treatment plans and procedures. It has traditionally been used in common procedures such as blood transfusions, and now its application is rapidly expanding to other branches of medicine, notably oncology. Unfortunately, many patients don’t end up receiving the most effective plans due to clinical practice gaps. For example, around only 36% of Non-small cell lung cancer patients get the right medication.

Considering the role of managed care pharmacy in this major public health trend, AMCP launched the AMCP Precision Medicine Initiative to better understand the causes and impacts of these implementation gaps and develop solutions to help patients get the life-changing therapies they deserve.

Key Opportunities in Precision Medicine

Accelerating alignment of coverage with clinical evidence: leveraging AMCP’s research to promote healthcare policy that reflects modern clinical guidelines and best practices
Advancing reflex biomarker testing at diagnosis: supporting the adoption of reflex testing to ensure timely, appropriate treatment pathways from the moment of diagnosis
Establishing a standardized quality metric for biomarker testing: leading efforts to create and implement a national standard for quality, consistency, and accountability across testing practices
Elevating precision medicine across the payer landscape: educating payers on what is required to fully implement precision medicine to improve patient outcomes

Submit a Use Case or Question

Testimonials

We’re aiming for meaningful change. Whether making sure insurance coverage reflects the latest science, encouraging automatic biomarker testing when cancer is diagnosed, setting a consistent quality standard, or helping precision medicine become a bigger priority across the health care system, we see incredible potential for improving patient well-being.

Susan A. Cantrell, RPh, MHL, CAE

Precision Medicine Access Ecosystem

The Precision Medicine Access Ecosystem visual displays patient access across the key players, policies, and technologies that shape how patients access evidence-based, affordable care. For managed care pharmacy professionals, it’s the framework that supports smarter decisions, better outcomes, and more equitable access. At AMCP, it drives our work to align stakeholders and improve medication access across the system through:

Clinical innovation with evidence-based coverage,
Benefit design with health equity and affordability, and
Stakeholder collaboration with policy and practice transformation.

View Precision Medicine Access Ecosystem

Listen to AMCP Unscripted Podcast on Precision Medicine

AMCP Unscripted Podcast - Jeff Dunn and Biomarkers, Targeted Therapy, and Managed Care Access

AMCP Unscripted guest, Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, about the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy and other managed care strategies.

Listen Now

Related Events

AMCP eLearning Day Focus on Proactive Health

eLearning Day: Focus on Precision Medicine and Proactive Health
Wednesday, August 13, 2025

11-12pm ET
[eLD 1] Advancing Precision Medicine in Breast Cancer: Targeted Therapies and the Role of Managed Care Pharmacy

1-2pm ET
[eLD 2] Preventative Health in Action: Advancing Shingles Vaccination in Special Populations

5-6pm ET Satellite Symposium
Leveraging the Latest Treatment Updates to Advance Managed Care Decision-Making in Eosinophilic Esophagitis: A 'Mock P&T' Initiative to Unlock the Potential of Novel Therapies

Featured Articles

JMCP Item June 13, 2025

Optimization of Oncology Biomarker Testing in Managed Care: Best Practices and Consensus Recommendations from an AMCP Market Insights Program

Precision medicine in oncology using actionable molecular biomarkers to guide treatment s

JMCP Item February 3, 2025

AMCP Partnership Forum: Managing Care in the Wave of Precision Medicine

Precision medicine, the customization of health care to an individual’s genetic profile while accounting for biomarkers and lifestyle, has increasingly been adopted by health care stakeholders to guide the development of treatment options, improve treatment decision making, provide more patient-centered care, and better inform coverage and reimbursement decisions. Despite these benefits, key challenges prevent its broader use and adoption.

JMCP Item February 3, 2025

A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine

This analysis addresses an important policy question: “What are potentially transformative strategies and methods to define and measure value at all levels of decision making that are aligned with personalized medicine/precision medicine (PM/PrM)?” To approach this question, we build on our previou

Press Releases December 14, 2017

AMCP Forum Discusses Strategies, Standards for Ushering in Era of Precision Medicine

View an AMCP press release on AMCP's Partnership Forum, "Managing Care in the Wave of Precision Medicine. "Precision medicine is no longer emerging, it's happening now," according to Susan A. Cantrell, RPh, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP).

Formulary & Utilization Management, Pre-Approval Information Exchange, Specialty Tiers, Value Framework

Precision Medicine Resources

Resource June 13, 2023

JMCP Outsert - Precision Oncology in NSCLC (Biomarker)

The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.

Precision Medicine

Resource May 9, 2020